Firstly, one of the questions asked in the webinar was whether,...

Firstly, one of the questions asked in the webinar was whether, if DCCR was approved next year, those taking it could still participate in any Phase 3 trial of NNZ-2591. The answer was that it was possible, provided it wasn’t within the exclusion criteria.

I’m fairly sure that it would be possible, if both therapies were approved, to take them concomitantly. They have different mechanisms of action. Perhaps results would be better than either drug used alone.

But I severely doubt that payers would agree to simultaneously reimburse both drugs for a patient if the potential combined cost was, say, US$800,000 per year.